ArticleCureus2025
Trends in Drug-Related Mortality in Adults Aged 40-59 in the United States (2018-2023): A Proxy Analysis of Polypharmacy Using CDC WONDER (Wide-Ranging Online Data for Epidemiologic Research).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDrug-related mortality is a crucial public health issue in the United States, especially among middle-aged adults, in whom polypharmacy raises the likelihood of adverse events. This study aims to explore the trends in drug-related deaths among adults aged 40-59 from 2018 to 2023 in the United States, using mortality as an exploratory proxy to investigate the broader implications of polypharmacy.
methodsA cross-sectional analysis was conducted using International Classification of Diseases, Tenth Revision (ICD-10)-specific codes from CDC WONDER (Wide-ranging ONline Data for Epidemiologic Research). For the years 2018-2023, crude mortality rates were evaluated for middle-aged individuals aged 40-59, classified into five age groups. Yearly trends were assessed to evaluate changes over time.
resultsThe age group 50-54 consistently demonstrated an elevated crude mortality rate, peaking in 2020. On the contrary, the 40-44 and 55-59 age groups showed lower rates with slight variations, particularly a visible increase was seen in 2020 among most age groups, coinciding with the COVID-19 pandemic, followed by stabilization in the subsequent years.
conclusionsDrug-related mortality in the United States is a significant issue among middle-aged adults, with the 50-54 age group displaying the highest rates. The noticeable rise in 2020 may indicate pandemic-related aspects, including healthcare accessibility, and a more psychosocial burden. These findings underline the need for focused measures to alleviate polypharmacy risks in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.